While the 5-year report of NOBLE was considered a win for CABG, the new data reinforce the role of PCI, with the still non-negligible caveat of higher rates of recurrent MI and repeat revascularization.
#Cardio_ed, #radial_first, #medical_education
The NOBLE study at 10 years is finally out and the conclusions are practice modifying in my opinion: at 10 years PCI and CABG were equal on all cause mortality with PCI showing higher rates of MI relapse and repeat revascularisation.
An implantable loop recorder (ILR) can be a game-changer in these 3 cases:
✅ Cryptogenic stroke
✅ Unexplained syncope after negative workup
✅ Infrequent unexplained palpitations
Long-term rhythm monitoring makes all the difference. #CardioEd #Cardio_Sky
@heartrhythmsociety.bsky.social
An implantable loop recorder (ILR) can be a game-changer in these 3 cases:
✅ Cryptogenic stroke
✅ Unexplained syncope after negative workup
✅ Infrequent unexplained palpitations
Long-term rhythm monitoring makes all the difference. #CardioEd #Cardio_Sky
@heartrhythmsociety.bsky.social
Super Helpful 👌
#cardiosky #medical_education #med_ed
Bottom line:
TAVR is proving safe, effective, and durable—even in low-risk patients.
ALIGN-AR opens doors for AR patients with no prior transcatheter options and high surgical risk.
#ACC25
Evolut Low Risk Trial:
TAVR vs. Surgery in patients with severe aortic stenosis + low surgical risk.
5-year outcomes:
TAVR = surgery in death/stroke
Better valve performance with TAVR
Durable quality of life
#ACC25
Why ALIGN-AR matters:
There’s currently NO FDA-approved transcatheter valve for native AR in the US.
This trial could lead to the first dedicated solution for high-risk AR patients.
#ACC25
ALIGN-AR Trial:
First major study focused specifically on high-risk patients with severe aortic regurgitation.
Device: JenaValve Trilogy THV
Result: >95% device success, low 30-day mortality & stroke, improved symptoms.
A game-changer for a previously untreatable group.
#ACC25
Big moves in structural heart disease! Two landmark trials—ALIGN-AR and Evolut Low Risk— from #ACC25 are shaping the future of aortic valve therapy. Quick breakdown:
Can't wait to read your book @gbiondizoccai.bsky.social
The photo is terrific by the way.
Coaching before high-stakes medical procedures could save lives, but implementation faces hurdles: time, workflow, and tradition.
Would the cultural and logistical shifts necessary be possible?
An interesting opinion piece from the @nytimes.com
#CardioSky #MedSky
www.nytimes.com/2025/01/06/o...
● Think about cardiac metastasis in cancer patients with LVH.
● Secondary cardiac tumors way more common than primary.
● Symptoms: nonspecific, leading to delayed diagnosis.
● CMR is the gold standard for tissue characterization and tumor diagnosis.
#whyCMR #CardioSky #MedSky
Waiting periods and available places in our rehab centers are obviously a major obstacle.
Was there an associated aneurysm? If yes did the patient present signs of ischaemia related to possible compression?
It's great to see this progress. Happy to be part of this new community.
Thank you.
I just learned about the new platform from a Twitter post. Migration ongoing. It's true that X is becoming too distracting.
Just learned about the BlueSky migration through this post. And i confirm that Twitter or X became too distracting for us scientists looking mainly to exchange with our peers throughout the world. So I'm migrating too.
#CardioSky #MedSky #MedEd
